Non Small Cell Lung Cancer Clinical Trials in San Diego, California

7 studies are recruiting for non small cell lung cancer in San Diego, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

   Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Clinical Study Site, San Diego, California

   Locations

   285 in total

   Run by

   Summit Therapeutics

   See if you can join NCT06767514 on ClinicalTrials.gov

2. Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

   This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line treatment of metastatic squamous non-small cell lung cancer. It is hypothesiz…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Sharp Memorial Hospital ( Site 9544), San Diego, California

   Locations

   216 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06422143 on ClinicalTrials.gov

3. A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California San Diego, Moores Cancer Center, San Diego, California

   Locations

   48 in total

   Run by

   Pierre Fabre Medicament

   See if you can join NCT04913285 on ClinicalTrials.gov

4. Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

   The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas a first-line therapy in participants with locally advanced or metastatic EGFRm (Ex19del and/or L858R) NSCLC. Study detai…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, San Diego, California

   Locations

   167 in total

   Run by

   AstraZeneca

   See if you can join NCT06350097 on ClinicalTrials.gov

5. Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

   This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California, San Diego; Moores Cancer Center, San Diego, California

   Locations

   66 in total

   Run by

   Genmab

   See if you can join NCT05579366 on ClinicalTrials.gov

6. BBO-11818 in Adult Subjects With KRAS Mutant Cancer

   A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California San Diego Moores Cancer Center, San Diego, California

   Locations

   17 in total

   Run by

   TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

   See if you can join NCT06917079 on ClinicalTrials.gov

7. EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer

   This is an open label, single arm, phase Ib/II clinical trial of checkpoint blockade, pembrolizumab and EZH2 inhibitor, tulmimetostat combination therapy for patients with advanced non-small cell lung cancer who have progressed from front or second-line treatment. Patients will be enrolled at multi…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   VA San Diego Healthcare System, San Diego, CA, San Diego, California

   Locations

   5 in total

   Run by

   VA Office of Research and Development

   See if you can join NCT05467748 on ClinicalTrials.gov